Skip to main content
Journal ArticleOPEN ACCESS

Rituximab in systemic sclerosis

  • Shevtsova T
  • Nadtocheeva V
  • Nimiritskaya S
  • et al.
Clinical pharmacology and therapy (2021) 30(2) 31-35
DOI: 10.32756/0869-5490-2021-2-31-35
N/ACitations
Citations of this article
23Readers
Mendeley users who have this article in their library.

Abstract

To evaluate the effect of intravenous rituximab, a monoclonal antibody to B-cells, on interstitial lung disease, skin fibrosis and arthritis in patients with systemic sclerosis (SSc).

Cite

CITATION STYLE

APA

Shevtsova, T., Nadtocheeva, V., Nimiritskaya, S., Akulkina, L., Bulanov, N., & Novikov, P. (2021). Rituximab in systemic sclerosis. Clinical Pharmacology and Therapy, 30(2), 31–35. https://doi.org/10.32756/0869-5490-2021-2-31-35

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free